Erlanger Health System

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation3 trials
• Myasthenia gravis3 trials
• Stroke2 trials
• Coronary artery disease1 trial
• Lung cancer1 trial
• Ulcerative colitis1 trial

Phase

• Phase 22 trials
• Phase 32 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Recruiting3 trials
• Active, not recruiting2 trials
• Completed2 trials
• Suspended1 trial
• Withdrawn1 trial

Lead sponsor

• argenx3 trials
• Conformal Medical, Inc2 trials
• Janssen Research & Development, LLC2 trials
• Salma Sabbour1 trial
• Yale University1 trial

Running trials

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· argenx· Source

  Contact: Joshua Alpers, MD

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· argenx· Source

  Contact: Joshua Alpers, MD

• Recruiting

  ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  NCT07284420· Phase 2· argenx· Source

  Contact: Joshua Alpers, MD

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  The CONFORMAL Early Feasibility Study

  NCT03616028· Conformal Medical, Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myasthenia gravis3 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

  Contact: Kevin N Sheth, MD

• Completed

  A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

  NCT03575793· Phase 1/2· Salma Sabbour· Source